Two mixed valence diruthenium(ii, iii) isomeric complexes show different anticancer properties. Issue 27 (23rd June 2021)

• Record Type: Journal Article
• Authors: Barresi, Elisabetta; Tolbatov, Iogann; Marzo, Tiziano; Zappelli, Elisa; Marrone, Alessandro; Re, Nazzareno; Pratesi, Alessandro; Martini, Claudia; Taliani, Sabrina; Da Settimo, Federico; La Mendola, Diego
• Is Part Of: Dalton transactions. Volume 50:Issue 27(2021)
• Page Start: 9643
• Page End: 9647
• Publication Date: 2021-06-23
• Subjects: Chemistry, Inorganic -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemistry, Inorganic -- Periodicals; 546.05
• DOI: 10.1039/d1dt01492g
• Languages: English
• ISSNs: 1477-9226

Abstract

Abstract : Two isomeric Ru2 (ii, iii ) mixed valence compounds show profoundly different anticancer properties due to their activation profiles and their ligands' chemical features. Abstract : In this paper it is demonstrated that the nature of the ligands of two Ru2 (ii, iii ) paddlewheel complexes dramatically affects the overall anticancer properties in cells. Herein, the complex [Ru2 (EB776)4 Cl] was found to be more active against a glioblastoma model with respect to its isomer [Ru2 (EB106)4 Cl]. These different effects depend on the steric hindrance, on the allowed conformations of the complexes and on the presence of hydrophilic regions in [Ru2 (EB776)4 Cl], which overall lead to a lower "steric protection".